Topicals

An emollient is an ingredient found in topical applications to soften and soothe skin. They are valuable and inexpensive treatment options for many individuals with mild to moderate psoriasis. When psoriasis is more severe, topicals are likely to be combined with oral medications, phototherapy, or biologics.

Emollients relieve symptoms of dryness and irritation while assisting in managing overgrowth and the shedding of skin cells that occurs with psoriasis. It can help soften plaques and cracks, enhance the skin’s ability to hold water and create a barrier that protects skin from bacteria and other irritants. As a result, this improves the skin’s barrier function and relieves inflammation. Emollients can be found in many different forms such as creams, lotions, ointments, foams, sprays, gels and shampoos and can be used directly on your skin.

Humectant and occlusive agents are the two key ingredients in a moisturizing product. The combination of ingredients determines the use and consistency of a product. Humectant enhances the skin’s ability to hold water and an occlusive agent slows water loss by creating a protective barrier on the skin’s surface.  These ingredients can feel thick and sticky, so manufacturers combine them with other substances to improve their ability to spread and penetrate the skin. Thicker products are often a good choice for people with psoriasis as they can prevent dryness but it’s best to consult with a physician to determine the ideal course of treatment.

When choosing a moisturizer for psoriasis, you may also want to consider the smell, ease of use, and the ingredients in the product. Hypoallergenic products (a product containing fewer allergy-producing substances) are commonly used as they less likely to irritate the skin. Some fragrances and chemicals found in moisturizers could further aggravate skin instead of relieving symptoms so it may be best to look for a fragrance-free lotion.

Dosage Form Considerations

VehicleConsistencyQualitySpeed of absorption/evaporation after application to the skinUseful for areas with hairOther considerations
OintmentViscousGreasySlowNoProvides an occlusive layer when applied to skin
GelThickNon-greasyModerateNoCooling sensation when applied to skin
CreamModerateNon-greasy to mildly greasyQuickMaybe
LotionThinNon-greasyVery QuickYesCooling sensation when applied to skin
FoamThinNon-greasyVery QuickYesSpreads easily
SolutionThinNon-greasyVery QuickYes
Scalp solutionVery ThinNon-greasyVery QuickYes
SprayVery ThinNon-greasyVery QuickMaybe
ShampooVery ThinNon-greasyQuickYesMust be left in place for 10-15 minutes before rinsing (follow product instructions)

List of Prescription Topical Treatment

How Does It Work?

Corticosteroids applied topically have the ability to decrease inflammation in the skin in many conditions, including psoriasis.

How Is It Used?

Topical corticosteroids are typically prescribed to be applied to psoriatic plaques twice daily. Topical corticosteroids are available in a variety of different potencies (strengths). Your doctor may prescribe a certain strength topical corticosteroid depending on the thickness of psoriasis plaques and their location on your body.

What are the possible side effects?

The most common side effect of topical corticosteroids is an initial mild burning or stinging feeling after application. Long-term use of strong corticosteroids can result in thinning of the skin. This should be monitored by you and your physician. 

Any Other Important Considerations?

Avoid covering the steroids with bandages or plastic wrap unless instructed to do so by your doctor.

What Medications Interact With This Treatment?

N/A

What Provinces and Territories List It On Formulary?

Varies depending on specific corticosteroid.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

How Does It Work?

Vitamin D3 analogues work by regulating skin cell production and proliferation (buildup), which is abnormal in psoriasis. Vitamin D3 analogues used to treat psoriasis include calcitriol (Silkis®) and calcipotriol (Dovonex®).

How Is It Used?

Vitamin D3 analogues are available as topical ointments and are applied as to the affected area of skin once or twice daily as directed by physician.

What are the possible side effects?

The most common side effect of vitamin D3 analogues is a temporary burning or stinging sensation when applied to the skin.

Any Other Important Considerations?

N/A

What Medications Interact With This Treatment?

N/A

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Coming soon.

How Does It Work?

The exact mechanism of tazarotene is unknown. It is thought to play a role in the differentiation of skin (i.e., it helps to control the multiplication of skin cells), and it may also help to regulate the immune system.

How Is It Used?

Tazarotene comes in both a gel and cream formulation. Typically, it is recommended to be applied to the affected area of skin once a day, usually at night. Improvement is typically noted within two months of treatment.

What are the possible side effects?

The most common side effect of topical retinoids is skin irritation. Redness, a burning sensation, dry skin, and skin shedding are commonly experienced with tazarotene, but these side effects tend to subside after a few weeks of treatment.

Any Other Important Considerations?

Tazarotene cannot be used during pregnancy.

Avoid unprotected exposure to sunlight and sunlamps as this product may increase the sensitivity of skin to ultraviolet light.

What Medications Interact With This Treatment?

No known significant drug interactions.

Product Monograph

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

How Does It Work?

The exact mechanism of anthralin and tars are unknown but they are thought to decrease the skin inflammation that is associated with psoriasis. Coal tar loosens and softens scales and crusts.

How Is It Used?

Anthralin:

Generally applied once daily or as directed by a doctor or pharmacist. When first starting to use anthralin, a short contact time of 5 – 10 minutes of the cream may be advised during the first week of treatment. Contact time can be gradually increased to up to 30 minutes, as tolerated by the skin. Anthralin can be removed by washing or showering.

When applying, gloves may be used to avoid staining of fingers and nails. Apply directly to plaques; rub in gently and avoid application to unaffected skin. Petroleum jelly may be used around the edges of the plaque to prevent irritation of unaffected skin.

Coal tar:

For scalp psoriasis, coal tar may be painted sparingly to the lesions 3-12 hours before shampooing.
For body psoriasis, apply coal tar to the lesions at bedtime.

Wash hands before and after application.

What are the possible side effects?

Anthralin: temporary skin irritation, temporary hair discolouration, temporary nail discolouration, temporary skin discolouration.

Coal tar: temporary skin irritation, increased skin sensitivity to light.

Any Other Important Considerations?

Anthralin is irritating to surrounding normal skin. It also stains skin and fabrics.

Coal tar has an odour and can stain skin and hair.

What Medications Interact With This Treatment?

N/A

Product Monograph

N/A

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

How Does It Work?

DUOBRII® is a lotion used on the skin to improve the signs and symptoms of psoriasis in adults.

DUOBRII® is a combination of two different medications. It contains halobetasol propionate, a corticosteroid, and tazarotene, a topical retinoid. Halobetasol propionate has the ability to decrease inflammation in the skin. Tazarotene is thought to work by helping with the normal growth of skin cells and by reducing inflammation.

How Is It Used?

Apply a thin layer once a day to affected skin. Rub in gently and wash your hands after application. Once your psoriasis is better, stop using DUOBRII® . It may then be used on and off as necessary, or as directed by your physician.

What are the possible side effects?

The most common side effects include contact dermatitis, a skin rash, or sores. Please consult the Product Monograph for more side effects.

Prolonged use of this product may cause the adrenal glands to become suppressed. Only use DUOBRII®  under the supervision of a physician.

Any Other Important Considerations?

Do not use DUOBRII® :

  • If you are allergic to halobetasol propionate, tazarotene or any of the other ingredients found in DUOBRII®.
  • If you are allergic to other corticosteroids or retinoic compounds.
  • On some other skin conditions (such as dermatitis, skin reactions after a vaccine, and infections).
  • If you are pregnant or if you think you might be pregnant.

Coal tar has an odour and can stain skin and hair.

What Medications Interact With This Treatment?

No known significant drug interactions.

Product Monograph

https://pdf.hres.ca/dpd_pm/00066402.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

How Does It Work?

Bryhali is a topical steroid, meaning it stops inflammation in areas that it is applied to which is helpful in treating plaque psoriasis.

How Is It Used?

Bryhali is a cream that is applied to areas of skin affected by plaque psoriasis. Bryhali should typically not be used for more than 8 weeks. There are several areas of the skin Bryhali should not be applied to because of risk of skin damage, so always talk to your doctor prior to using Bryhali to establish the appropriate amount to use and appropriate area of use.

What are the possible side effects?

Possible side effects of Bryhali include reaction of the skin the cream is applied to, including change in appearance of the skin as well as burning or itching skin. Less common side effects include increased risk of infection, cough, and high blood pressure. To obtain a comprehensive list of all potential side effects, talk to your doctor or pharmacist.

Any Other Important Considerations?

Bryhali should typically not be used for more than 8 weeks. Bryhali should typically be used with caution if you have any skin infections or history of high blood pressure

What Medications Interact With This Treatment?

There are no known drug interactions with Bryhali, but always check with your doctor prior to starting Bryhali to rule out any possibility of drug interaction.

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00060714.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

How Does It Work?

Roflumilast is a non-steroid selective inhibitor of phosphodiesterase 4 (PDE4), used for the topical treatment of plaque psoriasis, including treatment of psoriasis in the intertriginous areas, in patients 12 years of age and older.

How Is It Used?

Apply roflumilast topically once a day to affected areas of the skin and rub in completely. Wash hands after application unless hands are the affected areas being treated.

If deemed medically necessary to use during breast-feeding, use roflumilast on the smallest area of the skin for the shortest duration possible. Do not apply roflumilast directly to the nipple and areola to avoid direct infant exposure.

Roflumilast is for topical use only and not for ophthalmic, oral, or intravaginal use.

What are the possible side effects?

The most common adverse drug reactions reported in clinical trials among patients with plaque psoriasis 12 years of age and older are diarrhea and headache. To obtain a comprehensive list of all known potential side effects of roflumilast, talk to your doctor or pharmacist.

Any Other Important Considerations?

Roflumilast is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C), and patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredients, or components of the container.

Roflumilast should not be used during labor and delivery. Roflumilast should only be used by a breast-feeding mother if deemed medically necessary, considering a potential risk to the baby. To minimize potential exposure to the breastfed infant via breast milk, use roflumilast on the smallest area of skin and for the shortest duration possible while breastfeeding. Do not to apply roflumilast directly to the nipple and areola to avoid direct infant exposure.

What Medications Interact With This Treatment?

No formal drug-drug interaction studies were conducted with roflumilast. For a complete list of medications that may interact with roflumilast and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Product Monograph

https://pdf.hres.ca/dpd_pm/00060714.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Public Drug Program Formulary Tables

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
AlbertaBiologics and BiosimilarsAbataceptOrencia®NoNo
AlbertaSystemic DrugsAcitretinSoriatane®YesN/A
AlbertaBiologics and BiosimilarsAdalimumabHumira®NoNo
AlbertaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
AlbertaBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
AlbertaBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
AlbertaSystemic DrugsApremilastOtezla®NoNo
AlbertaBiologics and BiosimilarsBimekizumabBimzelxYes – S/ANo
AlbertaBiologics and BiosimilarsBrodalumabSiliq™NoN/A
AlbertaSystemic DrugsCelecoxibCelebrexNoNo
AlbertaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
AlbertaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
AlbertaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
AlbertaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
AlbertaSystemic DrugsCyclosporineYes – S/AN/A
AlbertaBiologics and BiosimilarsEtanerceptEnbrel®NoNo
AlbertaBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
AlbertaBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsEtanerceptRymtiYes - S/AYes - S/A
AlbertaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
AlbertaBiologics and BiosimilarsGuselkumabTremfya®Yes - S/AYes - S/A
AlbertaPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®Yes - S/AN/A
AlbertaBiologics and BiosimilarsInfliximabRemicade®NoNo 
AlbertaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsAbataceptOrencia®NoNo
British ColumbiaSystemic DrugsAcitretinSoriatane®YesN/A
British ColumbiaBiologics and BiosimilarsAdalimumabHumira®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
British ColumbiaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabAbriladaYes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabSimlandiYes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabYuflymaYes - S/AYes - S/A
British ColumbiaSystemic DrugsApremilastOtezla®NoNo
British ColumbiaBiologics and BiosimilarsBimekizumabBimzelxYes - S/ANo
British ColumbiaBiologics and BiosimilarsBrodalumabSiliq™NoN/A
British ColumbiaSystemic DrugsCelecoxibCelebrexNoYes – S/A
British ColumbiaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes - S/A
British ColumbiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
British ColumbiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
British ColumbiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamNoN/A
British ColumbiaSystemic DrugsCyclosporineYes – S/AN/A
British ColumbiaBiologics and BiosimilarsetanerceptEnbrel®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
British ColumbiaBiologics and BiosimilarsEtanerceptErelzi™Yes - S/AYes – S/A
British ColumbiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/AYes – S/A
British ColumbiaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
British ColumbiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
British ColumbiaPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
British ColumbiaBiologics and BiosimilarsInfliximabRemicade®NoNo 
British ColumbiaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
ManitobaBiologics and BiosimilarsAbataceptOrencia®NoNo
ManitobaSystemic DrugsAcitretinSoriatane®, Mint-Acitretin, Taro-AcitretinYesN/A
ManitobaBiologics and BiosimilarsAdalimumabHumira®Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriasis.Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriatic arthritis.
ManitobaBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabAbriladaYes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabSimlandiYes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabYuflymaYes - EDSYes - EDS
ManitobaSystemic DrugsApremilastOtezla®NoNo
ManitobaBiologics and BiosimilarsBimekizumabBimzelxYes - EDSNo
ManitobaSystemic DrugsCelecoxibCelebrex, CelecoxibYesYes
ManitobaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
ManitobaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
ManitobaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
ManitobaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
ManitobaSystemic DrugsCyclosporineRequires EDS, delete this row?YesN/A
ManitobaSystemic DrugsCyclosporineNeoral, Cyclosporine(Strides), Sandoz CyclosporineYes – EDSN/A
ManitobaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis.Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis.
ManitobaBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS  Yes – EDS
ManitobaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
ManitobaBiologics and BiosimilarsGuselkumabTremfya®Yes - EDSYes - EDS
ManitobaPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®YesN/A
ManitobaBiologics and BiosimilarsInfliximabRemicade®Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.
ManitobaBiologics and BiosimilarsInfliximabAvsola®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
New BrunswickBiologics and BiosimilarsAbataceptOrencia®NoNo
New BrunswickSystemic DrugsAcitretinSoriatane®YesN/A
New BrunswickBiologics and BiosimilarsAdalimumabHumira®NoNo
New BrunswickBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
New BrunswickSystemic DrugsApremilastOtezla®NoNo
New BrunswickBiologics and BiosimilarsBimekizumabBimzelxYes – S/ANo
New BrunswickBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
New BrunswickSystemic DrugsCelecoxibCelebrexN/AYes
New BrunswickBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
New BrunswickPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
New BrunswickPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
New BrunswickPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
New BrunswickSystemic DrugsCyclosporineYesN/A
New BrunswickBiologics and BiosimilarsEtanerceptEnbrel®NoNo
New BrunswickBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
New BrunswickBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsEtanerceptRymtiYes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
New BrunswickBiologics and BiosimilarsGuselkumabTremfya®Yes – S/AYes – S/A
New BrunswickPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®YesN/A
New BrunswickBiologics and BiosimilarsInfliximabRemicade®NoNo
New BrunswickBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAbataceptOrencia®NoNo
Newfoundland and LabradorSystemic DrugsAcitretinSoriatane®YesN/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHumira®Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
Newfoundland and LabradorSystemic DrugsApremilastOtezla®NoNo
Newfoundland and LabradorBiologics and BiosimilarsBimekizumabBimzelxYes – S/ANo
Newfoundland and LabradorBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
Newfoundland and LabradorSystemic DrugsCelecoxibN/AYes
Newfoundland and LabradorBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
Newfoundland and LabradorPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – S/AN/A
Newfoundland and LabradorPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
Newfoundland and LabradorPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
Newfoundland and LabradorSystemic DrugsCyclosporineYesN/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptEnbrel®NoNo
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/A Yes – S/A 
Newfoundland and LabradorBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsGuselkumabTremfya®Yes – S/A Yes – S/A 
Newfoundland and LabradorPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®Yes – S/A N/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemicade®Yes – S/A; Inflectra or Renflexis are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). No
Newfoundland and LabradorBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - SA
Newfoundland and LabradorBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
NIHBBiologics and BiosimilarsAbataceptOrencia®NoNo
NIHBSystemic DrugsAcitretinSoriatane®YesN/A
NIHBBiologics and BiosimilarsAdalimumabHumira®Yes- only for clients who received approval for Humira before June 11, 2021Yes- only for clients who received approval for Humira before June 11, 2021
NIHBBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabAbriladaYes – L/UYes – S/A
NIHBBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
NIHBSystemic DrugsApremilastOtezla®YesNo 
NIHBBiologics and BiosimilarsBimekizumabBimzelxNoNo
NIHBBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
NIHBSystemic DrugsCelecoxibCelebrexN/AYes
NIHBBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U
NIHBPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
NIHBPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
NIHBPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
NIHBSystemic DrugsCyclosporineCyclosporineYesYes
NIHBBiologics and BiosimilarsEtanerceptEnbrel®NoYes- Only for clients who received approval for Enbrel before October 2, 2017
NIHBBiologics and BiosimilarsEtanerceptErelzi™NoYes- L/U
NIHBBiologics and BiosimilarsEtanerceptBrenzys®NoYes - L/U
NIHBBiologics and BiosimilarsEtanerceptRymtiNoYes - L/U
NIHBBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
NIHBBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - L/U
NIHBPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®YesN/A
NIHBBiologics and BiosimilarsInfliximabRemicade®NoNo
NIHBBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAbataceptOrencia®NoNo
Northwest TerritoriesSystemic DrugsAcitretinSoriatane®YesN/A
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAbriladaYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
Northwest TerritoriesSystemic DrugsApremilastOtezla®Yes - L/UNo
Northwest TerritoriesBiologics and BiosimilarsBimekizumabBimzelxNoNo
Northwest TerritoriesBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
Northwest TerritoriesSystemic DrugsCelecoxibCelebrexN/AYes
Northwest TerritoriesBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U
Northwest TerritoriesPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
Northwest TerritoriesPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
Northwest TerritoriesPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
Northwest TerritoriesSystemic DrugsCyclosporineYesYes
Northwest TerritoriesBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptBrenzys®NoYes - L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptRymtiNoYes - L/U
Northwest TerritoriesBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
Northwest TerritoriesBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - L/U
Northwest TerritoriesPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®YesN/A
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemicade®NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
Nova ScotiaBiologics and BiosimilarsAbataceptOrencia®NoNo
Nova ScotiaSystemic DrugsAcitretinSoriatane®YesN/A
Nova ScotiaBiologics and BiosimilarsAdalimumabHumira®Yes- only for clients who received approval for Humira before December 15, 2021Yes- only for clients who received approval for Humira before December 15, 2021
Nova ScotiaBiologics and BiosimilarsAdalimumabHadlima®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabIdacio®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabAmgevita®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabHulio®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabAbriladaYes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabSimlandiYes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabYuflymaYes – EDSYes – EDS
Nova ScotiaSystemic DrugsApremilastOtezla®YesYes
Nova ScotiaBiologics and BiosimilarsBimekizumabBimzelxYes – EDSNo
Nova ScotiaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/A
Nova ScotiaSystemic DrugsCelecoxibCelebrexN/ANo
Nova ScotiaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
Nova ScotiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – EDSN/A
Nova ScotiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
Nova ScotiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes – EDSN/A
Nova ScotiaSystemic DrugsCyclosporineYesN/A
Nova ScotiaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  
Nova ScotiaBiologics and BiosimilarsEtanerceptErelzi™NoYes – EDS
Nova ScotiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsEtanerceptRymtiYes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
Nova ScotiaBiologics and BiosimilarsGuselkumabTremfya®Yes – EDSYes – EDS
Nova ScotiaPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
Nova ScotiaBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. 
Nova ScotiaBiologics and BiosimilarsInfliximabAvsola®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
NunavutBiologics and BiosimilarsAdalimumabAbriladaYes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
NunavutSystemic DrugsLeflunomideArava®N/AYes
NunavutBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsBimekizumabBimzelxNoNo
NunavutBiologics and BiosimilarsEtanerceptBrenzys®NoYes - L/U
NunavutPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
NunavutPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
NunavutSystemic DrugsCelecoxibCelebrexN/AYes
NunavutBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U
NunavutBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
NunavutPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
NunavutPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
NunavutPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®YesN/A
NunavutBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
NunavutPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
NunavutBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/U
NunavutBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
NunavutBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
NunavutBiologics and BiosimilarsInfliximabOmvyence™NoNo
NunavutBiologics and BiosimilarsAbataceptOrencia®NoNo
NunavutSystemic DrugsApremilastOtezla®YesNo
NunavutBiologics and BiosimilarsInfliximabRemicade®NoNo
NunavutBiologics and BiosimilarsInfliximabRemsima™NoNo
NunavutBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAbataceptOrencia®N/ANo. EAP may cover in specific clinical circumstances. 
OntarioSystemic DrugsAcitretinSoriatane®YesN/A
OntarioBiologics and BiosimilarsAdalimumabAbriladaYes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHumira®Yes - EAPYes - EAP
OntarioBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
OntarioSystemic DrugsApremilastOtezla®YesYes
OntarioBiologics and BiosimilarsBimekizumabBimzelxYes - L/UNo
OntarioBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
OntarioSystemic DrugsCelecoxibCelebrexN/ANo
OntarioBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EAP
OntarioPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – in specific clinical situationsN/A
OntarioPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYes – in specific clinical situationsN/A
OntarioPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes – in specific clinical situationsN/A
OntarioSystemic DrugsCyclosporineYesN/A
OntarioBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U Yes – L/U
OntarioBiologics and BiosimilarsEtanerceptEnbrel®Yes - EAPYes - EAP
OntarioBiologics and BiosimilarsEtanerceptErelzi™Yes – L/U Yes – L/U
OntarioBiologics and BiosimilarsEtanerceptRymtiYes - L/UYes - L/U
OntarioBiologics and BiosimilarsGolimumabSimponi®N/AYes - EAP
OntarioBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - EAP
OntarioPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®YesN/A
OntarioBiologics and BiosimilarsInfliximabAvsola®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsInfliximabOmvyence™NoNo
Prince Edward IslandBiologics and BiosimilarsAbataceptOrencia®NoNo
Prince Edward IslandSystemic DrugsAcitretinSoriatane®YesN/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHadlima®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
Prince Edward IslandSystemic DrugsApremilastOtezla®NoNo
Prince Edward IslandBiologics and BiosimilarsBimekizumabBimzelxYes – S/ANo
Prince Edward IslandBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
Prince Edward IslandSystemic DrugsCelecoxibN/AYes
Prince Edward IslandBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
Prince Edward IslandPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
Prince Edward IslandPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
Prince Edward IslandPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
Prince Edward IslandSystemic DrugsCyclosporineYesN/A
Prince Edward IslandBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A
Prince Edward IslandBiologics and BiosimilarsGuselkumabTremfya®Yes – S/AYes – S/A
Prince Edward IslandPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
Prince Edward IslandBiologics and BiosimilarsInfliximabRemicade®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAbataceptOrencia®NoNo
QuebecSystemic DrugsAcitretinSoriatane®YesN/A
QuebecBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. If treatment began before August 19, 2020.Yes - S/A. If treatment began before August 19, 2020.
QuebecBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
QuebecBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabAmgevita®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
QuebecSystemic DrugsApremilastOtezla®Yes – S/ANo
QuebecBiologics and BiosimilarsBimekizumabBimzelxYes – S/ANo
QuebecBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
QuebecSystemic DrugsCelecoxibCelebrexN/AYes
QuebecBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
QuebecPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – S/AN/A
QuebecPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYes – S/AN/A
QuebecPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes – S/AN/A
QuebecSystemic DrugsCyclosporineYesN/A
QuebecBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
QuebecBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/A 
QuebecBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsEtanerceptRymtiYes – S/AYes – S/A
QuebecBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
QuebecBiologics and BiosimilarsGuselkumabTremfya®Yes - S/ANo
QuebecPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®Yes - S/AN/A
QuebecBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
QuebecBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
QuebecBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAbataceptOrencia®NoNo
SaskatchewanSystemic DrugsAcitretinSoriatane®Yes – EDSN/A
SaskatchewanBiologics and BiosimilarsAdalimumabHumira®NoNo
SaskatchewanBiologics and BiosimilarsAdalimumabHadlima®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabHyrimoz®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabIdacio®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabAmgevita®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabHulio®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabAbriladaYes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabSimlandiYes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabYuflymaYes – EDSYes – EDS
SaskatchewanSystemic DrugsApremilastOtezla®NoNo
SaskatchewanBiologics and BiosimilarsBimekizumabBimzelxYes - EDSNo
SaskatchewanBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSNo
SaskatchewanSystemic DrugsCelecoxibCelebrexYesYes
SaskatchewanBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
SaskatchewanPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
SaskatchewanPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
SaskatchewanPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
SaskatchewanSystemic DrugsCyclosporineYes – EDSN/A
SaskatchewanBiologics and BiosimilarsEtanerceptEnbrel®NoNo
SaskatchewanBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS Yes – EDS
SaskatchewanBiologics and BiosimilarsEtanerceptBrenzys®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
SaskatchewanBiologics and BiosimilarsGuselkumabTremfya®Yes - EDSYes - EDS
SaskatchewanPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®YesN/A
SaskatchewanBiologics and BiosimilarsInfliximabRemicade®NoNo
SaskatchewanBiologics and BiosimilarsInfliximabAvsola®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
YukonBiologics and BiosimilarsAbataceptOrencia®NoNo
YukonSystemic DrugsAcitretinSoriatane®Yes – EDSN/A
YukonBiologics and BiosimilarsAdalimumabHumira®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabAbriladaYes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabSimlandiYes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabYuflymaYes - EDSYes - EDS
YukonSystemic DrugsApremilastOtezla®NoNo
YukonBiologics and BiosimilarsBimekizumabBimzelxNoNo
YukonBiologics and BiosimilarsBrodalumabSiliq™NoN/A
YukonSystemic DrugsCelecoxibN/AYes
YukonBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
YukonPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
YukonPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
YukonPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
YukonSystemic DrugsCyclosporineYesN/A
YukonBiologics and BiosimilarsEtanerceptEnbrel®Yes - EDS ; all new etanercept patients will be covered for Brenzys or ErelziYes – EDS; all new etanercept patients will be covered for Erelzi 
YukonBiologics and BiosimilarsEtanerceptErelzi™Yes - EDSYes – EDS
YukonBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes – EDS
YukonBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
YukonBiologics and BiosimilarsGuselkumabTremfya®NoNo
YukonPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
YukonBiologics and BiosimilarsInfliximabRemicade®Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.
YukonBiologics and BiosimilarsInfliximabAvsola®NoNo
YukonBiologics and BiosimilarsInfliximabInflectra®Yes - EDSYes - EDS
AlbertaBiologics and BiosimilarsInfliximabOmvyence™NoNo
AlbertaBiologics and BiosimilarsInfliximabRemsima™NoNo
AlbertaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
AlbertaSystemic DrugsLeflunomideArava®NoNo
AlbertaSystemic DrugsMethotrexateYesYes
AlbertaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
British ColumbiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
British ColumbiaBiologics and BiosimilarsInfliximabRemsima™NoNo
British ColumbiaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
British ColumbiaSystemic DrugsLeflunomideArava®YesYes
British ColumbiaSystemic DrugsMethotrexateYesYes
British ColumbiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
ManitobaBiologics and BiosimilarsInfliximabOmvyence™NoNo
ManitobaBiologics and BiosimilarsInfliximabRemsima™NoNo
ManitobaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsIxekizumabSiliq™Yes – EDSN/A
ManitobaSystemic DrugsLeflunomideArava®NoNo
ManitobaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
New BrunswickBiologics and BiosimilarsInfliximabOmvyence™NoNo
New BrunswickBiologics and BiosimilarsInfliximabRemsima™NoNo
New BrunswickBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
New BrunswickSystemic DrugsLeflunomideArava®N/AYes
New BrunswickSystemic DrugsMethotrexateYesYes
New BrunswickBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabOmvyence™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemsima™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Newfoundland and LabradorSystemic DrugsLeflunomideArava®N/AYes
Newfoundland and LabradorSystemic DrugsMethotrexateYesYes
Newfoundland and LabradorBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
NIHBBiologics and BiosimilarsInfliximabOmvyence™NoNo
NIHBBiologics and BiosimilarsInfliximabRemsima™NoNo
NIHBBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
NIHBSystemic DrugsLeflunomideArava®YesYes
NIHBSystemic DrugsMethotrexateYesYes
NIHBBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
Northwest TerritoriesBiologics and BiosimilarsInfliximabOmvyence™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemsima™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
Northwest TerritoriesSystemic DrugsLeflunomideArava®N/AYes
Northwest TerritoriesSystemic DrugsMethotrexateYesYes
Northwest TerritoriesBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
Nova ScotiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabRemsima™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
Nova ScotiaSystemic DrugsLeflunomideArava®N/AYes
Nova ScotiaSystemic DrugsMethotrexateYesYes
Nova ScotiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
NunavutSystemic DrugsUpadacitinibRinvoq®N/ANo
NunavutBiologics and BiosimilarsEtanerceptRymtiNoYes - L/U
NunavutBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
NunavutBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
NunavutBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
NunavutBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
NunavutSystemic DrugsAcitretinSoriatane®YesN/A
OntarioBiologics and BiosimilarsInfliximabRemicade®Yes - EAPYes - EAP
OntarioBiologics and BiosimilarsInfliximabRemsima™NoNo
OntarioBiologics and BiosimilarsInfliximabRenflexis®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes - EAP
OntarioSystemic DrugsLeflunomideArava®YesYes
OntarioSystemic DrugsMethotrexateYesYes
OntarioBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
Prince Edward IslandBiologics and BiosimilarsInfliximabOmvyence™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabRemsima™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Prince Edward IslandSystemic DrugsLeflunomideArava®N/AYes
Prince Edward IslandSystemic DrugsMethotrexateYesYes
Prince Edward IslandBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/A N/A
QuebecBiologics and BiosimilarsInfliximabOmvyence™NoNo
QuebecBiologics and BiosimilarsInfliximabRemsima™NoNo
QuebecBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
QuebecBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
QuebecSystemic DrugsLeflunomideArava®N/AYes
QuebecSystemic DrugsMethotrexateYesYes
QuebecBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
SaskatchewanBiologics and BiosimilarsInfliximabOmvyence™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabRemsima™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
SaskatchewanSystemic DrugsLeflunomideArava®NoYes – EDS
SaskatchewanSystemic DrugsMethotrexateYesYes
SaskatchewanBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
YukonBiologics and BiosimilarsInfliximabOmvyence™NoNo
YukonBiologics and BiosimilarsInfliximabRemsima™NoNo
YukonBiologics and BiosimilarsInfliximabRenflexis®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsIxekizumabTaltz®Yes - EDSYes - EDS
YukonSystemic DrugsLeflunomideArava®NoNo
YukonSystemic DrugsMethotrexateYesYes
YukonBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
AlbertaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
AlbertaSystemic DrugsSulfasalazineYesYes
AlbertaBiologics and BiosimilarsTildrakizumabIlumya™Yes - SAN/A
AlbertaSystemic DrugsTofacitinibXeljanz®N/ANo
AlbertaPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
AlbertaSystemic DrugsUpadacitinibRinvoq®N/AYes – S/A
AlbertaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
AlbertaBiologics and BiosimilarsUstekinumabWezlanaYes – S/ANo
AlbertaBiologics and BiosimilarsUstekinumabJamtekiYes – S/ANo
AlbertaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
AlbertaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
British ColumbiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
British ColumbiaSystemic DrugsSulfasalazineSalazopyrinYesYes
British ColumbiaBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
British ColumbiaSystemic DrugsTofacitinibXeljanz®N/ANo
British ColumbiaPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
British ColumbiaSystemic DrugsUpadacitinibRinvoq®N/ANo
British ColumbiaBiologics and BiosimilarsUstekinumabStelara®Yes – S/A until Dec 3 2024No
British ColumbiaBiologics and BiosimilarsUstekinumabJamtekiYes - S/AYes - S/A
British ColumbiaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
British ColumbiaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
ManitobaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
ManitobaSystemic DrugsSulfasalazinepms-Sulfasalazine, SalazopyrinYesYes
ManitobaBiologics and BiosimilarsTildrakizumabIlumya™Yes - EDSN/A
ManitobaSystemic DrugsTofacitinibXeljanz®N/ANo
ManitobaPrescription Topical TreatmentsTopical RetinoidsTazaroteneNoN/A
ManitobaSystemic DrugsUpadacitinibRinvoq®N/AYes - EDS
ManitobaBiologics and BiosimilarsUstekinumabStelara®Yes – EDSNo
ManitobaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
ManitobaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
New BrunswickBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
New BrunswickSystemic DrugsSulfasalazineSalazopyrinN/AYes
New BrunswickBiologics and BiosimilarsTildrakizumabIlumya™Yes - SAN/A
New BrunswickSystemic DrugsTofacitinibXeljanz®N/ANo
New BrunswickPrescription Topical TreatmentsTopical RetinoidsTazaroteneYes – S/AN/A
New BrunswickSystemic DrugsUpadacitinibRinvoq®N/AYes – S/A
New BrunswickBiologics and BiosimilarsUstekinumabStelara®NoNo
New BrunswickBiologics and BiosimilarsUstekinumabJamtekiYes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsUstekinumabWezlanaYes - S/AYes - S/A
New BrunswickPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
New BrunswickPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
Newfoundland and LabradorBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Newfoundland and LabradorSystemic DrugsSulfasalazineN/AYes
Newfoundland and LabradorBiologics and BiosimilarsTildrakizumabIlumya™Yes – S/AN/A
Newfoundland and LabradorSystemic DrugsTofacitinibXeljanz®N/ANo
Newfoundland and LabradorPrescription Topical TreatmentsTopical RetinoidsTazaroteneNoN/A
Newfoundland and LabradorSystemic DrugsUpadacitinibRinvoq®N/AYes – S/A 
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabJamtekiYes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabWezlanaYes – S/AYes – S/A
Newfoundland and LabradorPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
Newfoundland and LabradorPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
NIHBBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
NIHBSystemic DrugsSulfasalazineYesYes
NIHBBiologics and BiosimilarsTildrakizumabIlumya™Yes – L/UN/A
NIHBSystemic DrugsTofacitinibXeljanz®N/ANo
NIHBPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
NIHBSystemic DrugsUpadacitinibRinvoq®N/AYes- L/U
NIHBBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
NIHBBiologics and BiosimilarsUstekinumabWezlanaYes - L/UYes - L/U
NIHBPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
NIHBPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
Northwest TerritoriesBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
Northwest TerritoriesSystemic DrugsSulfasalazineN/AYes
Northwest TerritoriesBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
Northwest TerritoriesSystemic DrugsTofacitinibXeljanz®NoNo
Northwest TerritoriesPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
Northwest TerritoriesSystemic DrugsUpadacitinibRinvoq®N/ANo
Northwest TerritoriesBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
Northwest TerritoriesBiologics and BiosimilarsUstekinumabWezlanaYes – L/UYes – L/U
Northwest TerritoriesPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
Northwest TerritoriesPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
Nova ScotiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes - EDS
Nova ScotiaSystemic DrugsSulfasalazineN/AYes
Nova ScotiaBiologics and BiosimilarsTildrakizumabIlumya™Yes – EDSN/A
Nova ScotiaSystemic DrugsTofacitinibXeljanz®N/ANo
Nova ScotiaPrescription Topical TreatmentsTopical RetinoidsTazaroteneYes – EDSN/A
Nova ScotiaSystemic DrugsUpadacitinibRinvoq®N/AYes – EDS
Nova ScotiaBiologics and BiosimilarsUstekinumabStelara®Yes - EDSNo
Nova ScotiaBiologics and BiosimilarsUstekinumabJamtekiYes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsUstekinumabWezlanaYes - EDSYes - EDS
Nova ScotiaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®Yes - EDSN/A
Nova ScotiaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
NunavutBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
NunavutBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
NunavutPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
NunavutBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsUstekinumabWezlanaYes – L/UYes – L/U
NunavutSystemic DrugsTofacitinibXeljanz®NoNo
NunavutBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
NunavutSystemic DrugsCyclosporineYesYes
NunavutSystemic DrugsMethotrexateYesYes
NunavutSystemic DrugsSulfasalazineN/AYes
OntarioBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes - EAP
OntarioSystemic DrugsSulfasalazineN/AYes
OntarioBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/A
OntarioSystemic DrugsTofacitinibXeljanz®N/ANo
OntarioPrescription Topical TreatmentsTopical RetinoidsTazaroteneNoN/A
OntarioSystemic DrugsUpadacitinibRinvoq®N/ANo
OntarioBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
OntarioBiologics and BiosimilarsUstekinumabJamtekiYes - L/UYes - L/U
OntarioBiologics and BiosimilarsUstekinumabWezlanaYes - L/UYes - L/U
OntarioPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®Yes – L/UN/A
OntarioPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®Yes – L/UN/A
Prince Edward IslandBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Prince Edward IslandSystemic DrugsSulfasalazineN/AYes
Prince Edward IslandBiologics and BiosimilarsTildrakizumabIlumya™Yes – S/AN/A
Prince Edward IslandSystemic DrugsTofacitinibXeljanz®NoNo
Prince Edward IslandPrescription Topical TreatmentsTopical RetinoidsTazaroteneNoN/A
Prince Edward IslandSystemic DrugsUpadacitinibRinvoq®N/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Prince Edward IslandPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
Prince Edward IslandPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
QuebecBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
QuebecSystemic DrugsSulfasalazineN/AYes
QuebecBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
QuebecSystemic DrugsTofacitinibXeljanz®N/ANo
QuebecPrescription Topical TreatmentsTopical RetinoidsTazaroteneNoN/A
QuebecSystemic DrugsUpadacitinibRinvoq®N/AYes – S/A 
QuebecBiologics and BiosimilarsUstekinumabStelara®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsUstekinumabJamtekiYes – S/AYes – S/A
QuebecBiologics and BiosimilarsUstekinumabWezlanaYes – S/AYes – S/A
QuebecPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
QuebecPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
SaskatchewanBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
SaskatchewanSystemic DrugsSulfasalazineN/AYes
SaskatchewanBiologics and BiosimilarsTildrakizumabIlumya™Yes - EDSN/A
SaskatchewanSystemic DrugsTofacitinibXeljanz®N/ANo
SaskatchewanPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
SaskatchewanSystemic DrugsUpadacitinibRinvoq®N/AYes – EDS
SaskatchewanBiologics and BiosimilarsUstekinumabStelara®Yes – EDSYes – EDS
SaskatchewanPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
SaskatchewanPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
YukonBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
YukonSystemic DrugsSulfasalazineN/AYes
YukonBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
YukonSystemic DrugsTofacitinibXeljanz®NoNo
YukonPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
YukonSystemic DrugsUpadacitinibRinvoq®N/ANo
YukonBiologics and BiosimilarsUstekinumabStelara®Yes – EDSNo
YukonPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
YukonPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A

Last updated May 31, 2024.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.